PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...

Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...

Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...

Web Punditstm, a trusted provider of Remote Desktop Protocol (RDP) services, announces the launch of its cost-effective and high-performance RDP solutions designed ...

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery.

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Volkswagen celebrated the Passat’s 50th anniversary. It was a quiet celebration, largely because Volkswagen was busy ...

Perth Zoo's last female elephant has left for her forever home in South Australia. Locals report seeing sparking and smoke near a power transmitter close to Arthur River, where a bushfire ripped ...